Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients

References

• Chen YC, Huang YT, Yang CC, et al. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: an analysis of 75 patients in Taiwan. PLoS One. 2020;15(12):e0244620. doi:10.1371/journal.pone.0244620
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12(12):Cd011535. doi:10.1002/14651858.CD011535.pub2
   PubMed Web of Science ®Google Scholar
• Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676–1684. doi:10.1111/jdv.15653
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018;45(3):279–286. doi:10.1111/1346-8138.14096
   PubMed Web of Science ®Google Scholar
• Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459–472. doi:10.1007/s40265-017-0709-1
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–2029. doi:10.1016/j.cellsig.2014.05.014
   PubMed Web of Science ®Google Scholar
• Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG. Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol. 2018;17(8):835–840.
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590. doi:10.1016/j.bcp.2012.01.001
   PubMed Web of Science ®Google Scholar
• Langley A, Beecker J. Management of common side effects of apremilast. J Cutan Med Surg. 2018;22(4):415–421. doi:10.1177/1203475417748886
   PubMed Web of Science ®Google Scholar
• Rademaker M, Rubel DM, Agnew K, et al. Psoriasis and cancer. An Australian/New Zealand narrative. Australas J Dermatol. 2019;60(1):12–18. doi:10.1111/ajd.12889
   PubMed Web of Science ®Google Scholar
• Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297. doi:10.3390/ijms18112297
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269. doi:10.1001/jamadermatol.2019.4029
   PubMed Web of Science ®Google Scholar
• Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134–142. doi:10.1016/j.jaad.2015.09.001
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75(1):99–105. doi:10.1016/j.jaad.2016.02.1164
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol. 2017;77(5):845–54.e5. doi:10.1016/j.jaad.2017.07.013
   PubMed Web of Science ®Google Scholar
• Peleva E, Exton LS, Kelley K, Kleyn CE, Mason KJ, Smith CH. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol. 2018;178(1):103–113. doi:10.1111/bjd.15830
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, Descalzo MA, Mason KJ, et al. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. Br J Dermatol. 2018;179(4):863–871. doi:10.1111/bjd.16715
   PubMed Web of Science ®Google Scholar
• Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310–7.e1. doi:10.1016/j.jaad.2017.01.052
   PubMed Web of Science ®Google Scholar
• Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20(2):119–130. doi:10.1002/pds.2046
   PubMed Web of Science ®Google Scholar
• Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68(12):1863–1869. doi:10.1136/ard.2008.102103
   PubMed Web of Science ®Google Scholar
• Freedman JD, Gottlieb AB, Lizzul PF. Physician performance measurement: tiered networks and dermatology (an opportunity and a challenge). J Am Acad Dermatol. 2011;64(6):1164–1169. doi:10.1016/j.jaad.2010.07.004
   Web of Science ®Google Scholar
• Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70(11):1895–1904. doi:10.1136/ard.2010.149419
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886–2895. doi:10.1002/art.22864
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64(10):1421–1426. doi:10.1136/ard.2004.033993
   PubMed Web of Science ®Google Scholar
• Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68(7):1136–1145. doi:10.1136/ard.2008.091025
   PubMed Web of Science ®Google Scholar
• LE BLAY P, Mouterde G, Barnetche T, Morel J, Combe B. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol. 2012;39(4):712–715. doi:10.3899/jrheum.110982
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–1050. doi:10.1016/j.jaad.2010.09.734
   PubMed Web of Science ®Google Scholar
• Kahn JS, Casseres RG, Her MJ, Dumont N, Gottlieb AB, Rosmarin D. Treatment of psoriasis with biologics and apremilast in patients with a history of malignancy: a retrospective chart review. J Drugs Dermatol. 2019;18(4):S1545961619P0387X.
   Web of Science ®Google Scholar
• Björkholm M, Hultcrantz M, Derolf ÅR. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? Best Pract Res Clin Haematol. 2014;27(2):141–153. doi:10.1016/j.beha.2014.07.003
   PubMed Web of Science ®Google Scholar
• Jacque N, Leblond V. [Chronic lymphocytic leukemia]. Presse Med. 2019;48(7–8 Pt 1):807–815. Norwegian. doi:10.1016/j.lpm.2019.07.019
   Web of Science ®Google Scholar